Skip to main content

Cardiovascular Drugs and Therapy

Ausgabe Sonderheft 1/2011

An Arginine-Vasopressin V2 receptor Antagonist, Tolvaptan, for Treatment of Heart Failure with Volume Overload - Evidence from Nonclinical Studies to Clinical Trials

Inhalt (11 Artikel)

Phase III Clinical Pharmacology Study of Tolvaptan

Takayuki Inomata, Tohru Izumi, Masunori Matsuzaki, Masatsugu Hori, Atsushi Hirayama

Effects of Tolvaptan on Systemic and Renal Hemodynamic Function in Dogs with Congestive Heart Failure

Toshiyuki Onogawa, Yuki Sakamoto, Shigeki Nakamura, Sunao Nakayama, Hiroyuki Fujiki, Yoshitaka Yamamura

Anti-edematous Effects of Tolvaptan in Experimental Rodent Models

Toshiki Miyazaki, Yuki Sakamoto, Tatsuya Yamashita, Koji Ohmoto, Hiroyuki Fujiki

Nonclinical Safety Profile of Tolvaptan

Akihide Oi, Katsumi Morishita, Takumi Awogi, Atsushi Ozaki, Masanao Umezato, Shinji Fujita, Eiji Hosoki, Hajime Morimoto, Nobuya Ishiharada, Hironobu Ishiyama, Tohru Uesugi, Masaya Miyatake, Tadashi Senba, Toshiyuki Shiragiku, Naoto Nakagiri, Norio Ito

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.